Biohaven to continue testing troriluzole in Alzheimer’s patients

Alzheimer’s is a progressive neurodegenerative disorder responsible for 60 to 80% of dementia cases. Credit: Gerd Altmann from Pixabay.



  • Biohaven to continue testing trigriluzole in Alzheimer's patients